after having previously received laser photocoagulation for extrafoveal or juxtafoveal CNV. The follow up interval following the ﬁrst PDT session ranged from 6 to 16 months (average 9 months) with 53% of the eyes followed for at least 9 months (equivalent of a maximum of 4 PDT sessions by TAP protocol). The number of treatment sessions over the period of follow-up ranged from 1 to 5 (average of 2.7 sessions). The average pre-treatment GLD was 2585 μm (range: 400–4800 μm) and the average post-treatment GLD was 2103 μm (range: 0–6800 μm). At the last follow up visit following PDT, 40 eyes (64%) had stable or decreased GLD of the lesion with no progression of leakage. Twenty-eight of 62 eyes (45%) had no evidence of CNV with absence of leakage (Figure 1). Twenty-two eyes (36%) had progression. Ten of these (45%) had at least A B PDT-lesion size-disciform scar doubling of the GLD of the neovascular lesion compared to pre-treatment. The latter could explain our observation that the average pre-treatment GLD (2585 μm) was not signiﬁcantly different from the average post-treatment GLD (2103 μm), although 64% of the eyes had stable or decreased GLD. Three study eyes (5%) developed a DS following PDT with an average scar size of 3200 ± 1345 μm (range: 2100–4700 μm) (Figure 2). Fourteen patients (23%) had already had disciform scarring in their fellow eye at the time of presentation, 6 of these (43%) had previous laser therapy for CNV (Table 1). None of these eyes had previously received PDT. At last follow up visit, all but one of the 14 patients had a GLD of the neovascular lesion in the study eye smaller than the size of the scar in the fellow eye; and 7 of them (50%), had no evidence of CNV with absence of leakage in the study eye (Table 1). The average size of the DS in these 14 fellow eyes was 5900 ± 1866 μm (range: 2200–9200 μm). The average size of the DS that developed in eyes with previous laser therapy (6/14) was 5500 ± 2365 μm (range: 2200–9200 μm) and that in eyes without previous intervention (8/14; naturally occurring) was 6200 ± 1493 μm (range: 4000–8000 μm) (Figure 3; Table 2). The average size of the DS that developed in 3 study eyes following PDT (3200 ± 1345 μm) was signiﬁcantly smaller than that of the fellow eyes of the subgroup of 14 patients (5900 ± 1866 μm), and than that of the 8 of 14 eyes without previous intervention (6200 ± 1493 μm) (Tables 2, 3). It was not signiﬁcantly smaller, however, than that of the 6 of 14 eyes that had disciform scaring with prior laser treatment (5500 ± 2365 μm) (Tables 2, 3). Figure 1 Pre-and post-treatment ﬂuorescein angiogram (FA) of the left eye of a patient withAMD-related predominantly classic SFCNV.A) Pre-treatment,late phase frame. B) Ten months after two sessions of PDT, late phase frame. Note absence of CNV leakage in the post-treatment angiogram. Abbreviations:AMD,age-related macular degeneration;CNV,choroidal neovasculariza- tion; PDT, photodynamic therapy; SFCNV, subfoveal choroidal neovascularization. Clinical Ophthalmology 2008:2(4) Figure 2 Disciform scar following PDT.Fundus picture of a patient withAMD-related SFCNV that evolved into a disciform scar following two sessions of PDT.This was the largest scar that developed following treatment (GLD: 4700 μm). Abbreviations:AMD,age-related macular degeneration;GLD,greatest linear dimension; PDT, photodynamic therapy; SFCNV, subfoveal choroidal neovascularization. 775